logo
Plus   Neg
Share
Email

Pfizer Announces EC Approval Of VYNDAQEL - Quick Facts

Pfizer Inc. (PFE) reported European Commission approval for VYNDAQEL, a 61 mg oral capsule, for the treatment of wild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy. The European Commission approval of VYNDAQEL is based on results from the Phase 3 ATTR-ACT study.

"Until today, there were no approved medicines to treat patients with ATTR-CM in the EU. VYNDAQEL is now the first treatment to have two formulations approved in the EU to treat manifestations of transthyretin amyloidosis: one for cardiomyopathy, and one
for stage 1 polyneuropathy," said Paul Levesque, Global President, Pfizer Rare Disease.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Arts and crafts chain Hobby Lobby has been ordered to shut its stores after the retailer reopened them by defying stay-at-home orders in various states amid the coronavirus pandemic. Ohio Attorney General Dave Yost said on Twitter that he sent a cease-and-desist letter following which the retailer agreed to close its stores on Wednesday night. Boston Scientific Corp. said Thursday that to lessen the impact of the coronavirus pandemic on its business, it will significantly reduce the salaries of its chief executive officer, directors and executive committee members. The company also intends to temporarily reduce work week schedules for employees, where appropriate. The medical device maker said these measures are to reduce costs. Marriott International announced a security data breach at its property system that hit up to approximately 5.2 million guests. The breached information is believed to exclude Marriott Bonvoy account passwords or PINs, payment card information, passport information, national IDs, or driver's license numbers. The latest incident, however, is less severe compared to the hotel chain's 2018 data breac
Follow RTT
>